Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) has been assigned an average broker rating score of 3.00 (Hold) from the one brokers that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating.
Zacks has also given Dipexium Pharmaceuticals an industry rank of 124 out of 265 based on the ratings given to its competitors.
ILLEGAL ACTIVITY NOTICE: “Zacks: Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) Given Consensus Rating of “Hold” by Brokerages” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.com-unik.info/2017/08/19/zacks-dipexium-pharmaceuticals-inc-nasdaqplxp-given-consensus-rating-of-hold-by-brokerages-updated-updated-updated.html.
An institutional investor recently bought a new position in Dipexium Pharmaceuticals stock. Heritage Way Advisors LLC acquired a new position in shares of Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) during the second quarter, according to its most recent filing with the SEC. The fund acquired 32,101 shares of the biotechnology company’s stock, valued at approximately $197,000. Heritage Way Advisors LLC owned about 0.37% of Dipexium Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 39.03% of the company’s stock.
Shares of Dipexium Pharmaceuticals (NASDAQ:PLXP) traded up 1.68% on Monday, hitting $6.05. The stock had a trading volume of 1,879 shares. The company has a 50-day moving average of $6.28 and a 200-day moving average of $8.80. Dipexium Pharmaceuticals has a 52-week low of $5.60 and a 52-week high of $142.01. The company’s market cap is $26.52 million.
Dipexium Pharmaceuticals Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Dipexium Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dipexium Pharmaceuticals Inc. and related companies.